Skip to content
Brand AI

Chugai

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    AstraZeneca and Chugai settle Ultomiris patent litigation

    Settlement

    AstraZeneca announced an agreement with Chugai Pharmaceutical resolving all patent disputes related to Ultomiris. Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022.

    Source excerpt

    • Under the terms of the agreement, Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022
    • AstraZeneca says agreement with Chugai Pharmaceutical resolving all patent disputes
    • Under the terms of the agreement, Alexion will make a single payment of $775m in the second quarter of 2022, for which a charge will be recognised through the non-core P&L in the first quarter of 2022.
    Source